InsiderClue
Stocks · Health care · Pharmaceutical Preparations

BioXcel Therapeutics, Inc.

BTAI Clue Score45
United States Fiscal year ends December CIK 0001720893
Alert on the numbers Alert on insider trades

Key numbers

Fiscal year 2025, ended 31 Dec 2025, as filed
Revenue
$642.00K
Net income
$69.90M
Free cash flow
$57.62M
Operating margin
-7,860.0%
Net margin
-10,887.4%
Return on capital
-282.1%
Revenue growth, 1 yr
-71.7%

Revenue and profit

Fiscal years, as filed with the SEC · point at a year for the detail
Full statements →
0K -82M FY20 Fiscal year 2020 Revenue $0.00 Net income $82.17M Margin n/a 0K -107M FY21 Fiscal year 2021 Revenue $0.00 Net income $106.93M Margin n/a 375K -166M FY22 Fiscal year 2022 Revenue $375.00K Net income $165.76M Margin -44,201.9% 1M -179M FY23 Fiscal year 2023 Revenue $1.38M Net income $179.05M Margin -12,974.9% · growth +268.0% 2M -60M FY24 Fiscal year 2024 Revenue $2.27M Net income $59.60M Margin -2,630.1% · growth +64.2% 642K -70M FY25 Fiscal year 2025 Revenue $642.00K Net income $69.90M Margin -10,887.4% · growth -71.7%
RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first
All of them →
DateInsiderTypeValueOf own stake
20 May 2026 Mehta Vimal
CEO and President
 Sold on a plan $21.11K 21.8%
20 May 2026 Steinhart Richard I
Chief Financial Officer
 Sold on a plan $7.43K 20.7%
20 May 2026 Yocca Frank
Chief Scientific Officer
 Sold on a plan $7.43K 20.7%
20 May 2026 Rodriguez Javier
See Remarks
 Sold on a plan $7.11K 19.7%
16 Dec 2024 Mehta Vimal
CEO and President
 Sold on a plan $1.13K 5.0%
16 Dec 2024 Steinhart Richard I
Chief Financial Officer
 Sold on a plan $206.98 2.7%